A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus

Qilu Pharmaceutical

Status and phase

Not yet enrolling

Phase 1

Conditions

Systemic Lupus Erythematosus

Treatments

Drug: QLS4131 for Injection.

Study type

Interventional

Funder types

Industry

Identifiers

NCT07001839

QLS4131-201

Details and patient eligibility

About

The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of QLS4131 in subjects with systemic lupus erythematosus (SLE). The main questions it aims to answer are:

The safety, tolerability and maximum tolerated dose (MTD) of QLS4131 for Injection in participants with SLE.
The recommended Phase 2 dose (RP2D) of QLS4131 for Injection in participants with SLE.

Participants will be administered different target dose of QLS4131 for Injection only once. A step-up dosing approach will be implemented at high dose level as determined by the safety monitoring committee.

Enrollment

108 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 18 to 70 (inclusive);
Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (ACR) Classification Criteria at least 12 weeks or more prior to screening;
Participants with positive antinuclear antibody (ANA) (≥ 1:80), or positive anti-dsDNA antibody and/or positive anti-Sm antibody at screening;
Active SLE disease at screening, as demonstrated by a SLEDAI-2K >= 8 at screening, or SLEDAI-2K >= 6 at the presence of low complement and/or positive anti-dsDNA antibodies;
Current receipt of one or more of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroids, antimalarial agents, and conventional immunosuppressants:
1. For participants receiving an oral corticosteroid, treatment with ≤40 mg/day prednisone or equivalent, at a dose that has been stable for at least 4 weeks prior to first dose;
2. For participants receiving an antimalarial, the medication(s) must have been at a stable dose ≥ 4 weeks prior to the first dose;
3. For participants receiving immunosuppressants, treatment with a single immunosuppressant at a stable dose for ≥ 4 weeks prior to the first dose: conventional immunosuppressants include azathioprine, mycophenolate mofetil, mycophenolic acid, and methotrexate (oral, subcutaneous or intravenous routes).
Participants who understand and abide by the study procedures, voluntarily participate in this study, and sign the Informed Consent Form in person.

Exclusion criteria

Participants with known intolerance or allergy to the investigational product or drugs that may be used in the study (e.g., Tocilizumab) and any components;
Participants with active severe active or unstable lupus-associated neuropsychiatric disease;
Participants with other autoimmune diseases that may affect the efficacy evaluation;
Participants with poorly controlled hypertension and diabetes;
Participants with severe lupus nephritis;
Participants with a history of malignancy within 5 years prior to screening;
Participants with a previous history of vital organ transplantation;
Participants who have had opportunistic infections within 12 weeks prior to the first dose;
Receipt of any CAR-T, CAR-NK or other gene therapy;
Pregnant or lactating women.